ProPhase Labs, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
ProPhase Labs, Inc. (PRPH) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $8.23 million as of 2021-08-10, per its 10-Q filed 2022-05-13.
Discontinued › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2022-05-13
- 2021-08-10: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $8.23M.
- 2020-10-23: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.60M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2021-08-10 | $8.23M 10-Q · filed 2022-05-13 |
| 2020-10-23 | $1.60M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |